Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study also evaluated the safety of ASP0113 in this patient population.
Participants were followed for one year after first study drug injection. This was the primary study period. Participants were followed for 4.5 years after completion of the primary study to assess long-term safety of the vaccine. ;